Optical Coherence Tomography (OCT) News
-
Showcase
PhotoniCare Announces FDA Clearance for First-In-Class Technology for Imaging the Ear
Champaign, Ill. – Jan. 6, 2020 – PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its TOMi™ Scope [OtoSight Middle Ear Scope] for non-invasive imaging of the middle ear. Using optical coherence ...
-
Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
Perimeter Medical Imaging AI and Pavilion Surgery Center Announce Placement of Perimeter S-Series OCT for Use at Ambulatory Surgery Center in Orange, CA
Pavilion Surgery Center, an affiliate of St. Joseph Hospital, along with Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today jointly announced ...
-
The Lancet Oncology: 66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics’ VivoSight OCT laser scanner
A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography (‘OCT’) technology, which can transform patient’s treatment and care of basal cell carcinomas (BCC). It was concluded that OCT-guided diagnosis, when compared to a ...
-
Notal Vision Reports Publication of First U.S. Home OCT Study Results
Manassas, VA (March 8th, 2022) - Digital healthcare provider Notal Vision today announced that results of the first U.S.-based study with its investigational home-based optical coherence tomography (OCT) platform have been published in Ophthalmology Retina1. The Notal Home OCT pipeline technology is designed to provide patient-initiated retinal OCT scans to support the management of patients with ...
-
Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baylor College of Medicine in Houston, TX
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the expansion of its ongoing pivotal study to include an additional clinical trial site at Baylor ...
-
Perimeter Medical Imaging AI Announces First Commercial Installation of Perimeter S-Series OCT in North Texas and Ongoing Market Development Activities Across the U.S.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the first commercial installation of its flagship Perimeter S-Series OCT system at a North ...
-
Perimeter Medical Imaging AI Announces Initiation of First Clinical Trial Site at West Cancer Center & Research Institute in Tennessee
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its ...
-
Perimeter Medical Imaging AI Announces Important Milestone in ATLAS AI Project With FDA Investigational Device Exemption (IDE) Approval to Launch Clinical Trial Using Perimeter B-Series OCT With ImgAssist AI in Breast Conservation Surgery
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced approval of its Investigational Device Exemption (“IDE”) application by the U.S. ...
-
Notal Vision Reports Results from First U.S. Home OCT Feasibility Study
Manassas, VA (October 12, 2021) - Notal Vision, Inc. reported today that results of the first U.S.-based feasibility study with its investigational home-based optical coherence tomography (OCT) platform were presented at the Retina Society and the American Society of Retina Specialists (ASRS) annual meetings. The Notal Home OCT pipeline technology is designed to provide patient-initiated retinal ...
-
Perimeter Medical Imaging AI Provides Corporate Update on Ramp-Up of its Commercial Organization
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today provided a corporate update on the progress made to date to grow its commercial organization. Under the ...
-
Perimeter Medical Imaging AI to Participate in Panel Discussion “Innovations in Breast Cancer Detection, Surgery and Treatment” at the Lytham Partners Summer 2021 Investor Conference
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)(FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that the Company's Chief Executive Officer, Jeremy Sobotta, will participate in a panel at the ...
-
AI Specialists Manchester Imaging Win UK Innovation Scholars Grant to Develop AI-enhanced Skin Cancer Detection Capability for Michelson Diagnostics’ VivoSight OCT Scanner
AI specialists Manchester Imaging Ltd have won a UK Innovation Scholars grant to support the parttime secondment of AI expert Tom Williams to skin scanner specialists Michelson Diagnostics Ltd over two years. Tom is working with Michelson to develop AI software that will process images of basal cell carcinoma, the most common form of skin cancer affecting millions worldwide, scanned by ...
-
PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope
PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that it is rebranding its middle ear scope to OtoSight™ Middle Ear Scope (formerly TOMi™ Scope). In preparation for the 2021 commercial launch, the OtoSight™ Middle Ear Scope brand name is well-positioned to convey the ...
-
Michelson Diagnostics teams up with AI Specialists Manchester Imaging to develop Machine Learning Algorithms for VivoSight OCT Skin Imaging System
Michelson Diagnostics Ltd, manufacturer of the world-leading VivoSight OCT skin imaging and measurement system, has teamed up with AI specialists Manchester Imaging Ltd, to aid dermatologists in the fight against skin cancer and other skin diseases. Michelson’s VivoSight Dx OCT scanner is used by trained dermatologists in their assessment of suspicious skin lesions, and is already in ...
-
Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases
Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Dr. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the novel technology during the Gene & Cell Therapy Spotlight session. The company’s ...
By Eyevensys
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you